Celmatix Launches MyFertility Compass™ to Give Women Better Insights into Their Family Building Journey
NEW YORK--(BUSINESS WIRE)--Jul 10, 2018--Today, Celmatix, the next-generation women’s health company, announced the launch of MyFertility Compass™, an online tool that helps women understand their personalized likelihoods of having a baby, with or without the use of common fertility treatments including in vitro fertilization. MyFertility Compass leverages world-class science to educate women about the factors that could influence their fertility while providing data-driven projections to help women better partner with their physicians on their family building journeys.
“We learned in our research that many women do not speak to their physicians when they are on their family building journeys and instead consult the internet. Our mission has always been to help women be more proactive about their fertility and health through better science and personalization,” said Dr. Piraye Yurttas Beim, founder and CEO of Celmatix. “It has been tremendously rewarding to see how our Polaris® platform has impacted over 90,000 patients at fertility centers and how our Fertilome® genetic test is bringing true personalized medicine to reproductive health. Both of these products are currently primarily accessed through specialist physicians so we wanted to build a tool that would impact more women, earlier in their journeys.”
MyFertility Compass is free and easy to use. When a woman who is currently trying to get pregnant visits www.myfertilitycompass.io, she will be asked to provide her age and to answer questions about her lifestyle and health that may impact her fertility. Using that information, MyFertility Compass generates a personalized fertility report. For women under 35 who have been trying for more than a year, and women over 35 who have been trying for at least six months, their personalized report will also include their estimated likelihoods of success under the care of a physician using basic or more advanced fertility treatments.
The models that power MyFertility Compass are based on a combination of peer-reviewed scientific studies and Celmatix’s own proprietary predictive models, which have been developed using a structured real world evidence dataset of nearly 1 million fertility treatment outcomes.
“As an OBGYN physician and fertility specialist, I know that many times women on their family building journeys worry too soon or more commonly not soon enough,” said Linda C. Giudice, MD, PhD, Distinguished Professor and the Robert B. Jaffe MD Endowed Professor in the Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco (UCSF), as well as a member of the Celmatix Scientific Advisory Board. “MyFertility Compass is an innovative and valuable resource that empowers women to assess their fertility potential and pathways to optimize achieving their goals of family building. Data-driven tools like MyFertility Compass can have a big impact by giving women more personalized and relevant insights. With the demographic trends of women waiting until later in life to start or expand their families, directing women to the right care at the right time is more important than ever.”
About Celmatix Inc.
Celmatix is a next-generation women’s health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them and their physicians with more personalized information. The company’s research-driven products include the Fertilome® test, the world’s first multigene panel test that reveals what a woman’s DNA says about her reproductive health, Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience, and MyFertility Compass™, a data-driven education tool that gives women who are currently trying to conceive insights into their fertility potential.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005189/en/
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: WOMEN TECHNOLOGY INTERNET HEALTH GENETICS BABY/MATERNITY CONSUMER GENERAL HEALTH
SOURCE: Celmatix Inc.
Copyright Business Wire 2018.
PUB: 07/10/2018 09:00 AM/DISC: 07/10/2018 09:01 AM